The story of copyright's flagship drug presents a nuanced case for investors in the drug sector. While initially a tremendous success, generating huge profits, the exclusivity end and the subsequent arrival of generic competitors have drastically impacted revenue. This presents questions about the long-term viability of similar therapeutic developm